Patent Law

The Center for Business Intelligence is hosting the above-titled conference in Philadelphia, PA on October 22-23, 2009.

Paragraph IV litigation is reaching an all-time high with almost $85 billion in product sales that potentially could be affected by pending litigation and more than twenty-five drugs going off patent before 2012.  Today?s pharmaceutical companies, both brand and generic, have much at stake in this costly, complex and constantly changing area of patent litigation.  CBI?s 2nd Annual Pharmaceutical Congress on Paragraph IV Disputes brings both sides of the issue together for two days of presentations and panel discussions to discuss litigation strategies, statutory guidelines, current cases and their landmark decisions.

 Confirmed Sessions Include:

    Inequitable Conduct and Exceptional Cases ? What Does Recent Case Law Tell Us?

        * Inequitable conduct and recent Federal Circuit decisions

              o Aventis Pharma v. Amphastar Pharmaceuticals and Teva 

        * Exceptional cases

              o What makes a case exceptional?

              o Assess Takeda v. Apotex and Alphapharm and prior ?exceptional? case examples

        Anthony J. Viola, Partner, Edwards Angell Palmer & Dodge LLP

    Analyze FTC Enforcement Activity and Reverse Payment Policy Initiatives

        * Evaluate continuing development of antitrust litigation

        * Analyze pending reverse payment policy and evaluate the force(s) behind it

        * Discuss authorized generics and their impact on competition

        * Understand the FTC?s findings in their report on FOB market entry and pioneer/FOB competition

        Saralisa Brau, Deputy Assistant Director, Health Care Division, Federal Trade Commission

Learn more and register here.